An observational study in Thrombi, Thrombus, Brain and Thrombus, sponsored by Tianjin Medical University. Recruiting at 3 sites in China. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Tianjin Medical University · Observational
In the field of diagnosing Thrombi diseases, it is now a well established practice to inject positron-emitting tracers into the human body.
These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own GPIIb/IIIa imaging agents.
This clinical research project aims to visualize abnormal tau pathology in the living human brain using [18F/68Ga]GP1 PET imaging. [18F/68Ga]GP1 is a small molcule-based tracer that offers stronger binding affinity to GPIIb/IIIa. The study primarily focuses on evaluating the safety and diagnostic efficacy of [18F/68Ga]GP1 PET imaging in human subjects.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
This study's planned enrollment of 500 is above the median of 173 across 384 observational studies indexed under Thrombosis.
Browse Thrombosis studies →Tianjin Medical University is the lead sponsor of 49 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
(i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated thrombi (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled GPIIb/IIIa PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single intravenous bolus injection of 10 ± 3 mCi of \[18F/68Ga\]GP1 followed by a PET/CT scan.
Diagnostic Test: 18F/68Ga-GP1
Participants will receive a single intravenous bolus injection of 10 ± 3 mCi of \[18F/68Ga\]GP1 followed by a PET/CT scan
Diagnostic Test: 18F/68Ga-GP1
Each subject receive a single intravenous injection of 18F/68Ga-GP1, and undergo PET/ CT or MRI imaging within the specificed time.
Standardized uptake value (SUV)
Standardized uptake value (SUV) of 18F/68Ga-GP1 for each target lesion of subject or suspected thrombi.
Time frame: 30 days
Diagnostic efficacy
The sensitivity, specificity and accuracy of GPIIb/IIIa PET/CT were calculated.
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2031, 60 months after the start.
Of 160 non-industry observational studies under Thrombosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 114. This study's planned 60 months is above that.
Counting every sponsor, half of 189 studies reached it within 31 months; a quarter within 12 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tianjin Medical University